GLP-1 Medications for Weight Loss Now Available!
                    
                    
                 
             
            
                                            
                The city of Portland, Oregon, currently has 3 active clinical trials seeking participants for Weight Loss research studies. 
            
                        
                                                                    
    
        
            
                
                                    VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
                                
            
            
         
        
     
    
        
            
                This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight             
        
        
            
                This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight 
Read Less
            
         
    
        
            
            
            
                Trial Updated:
                08/12/2025
             
         
        
            Locations: Viking Clinical Site #2097, Portland, Oregon  
+1 locations          
        
                            Viking Clinical Site #2097, Portland, Oregon
                            Viking Clinical Site #2126, Portland, Oregon
                     
        
            
        
     
                             
    
        
            
                
                                    VK2735 for Weight Management Phase 3
                                
            
            
         
        
     
    
        
            
                This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.             
        
        
            
                This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes. 
Read Less
            
         
    
        
            
            
            
                Trial Updated:
                08/12/2025
             
         
        
            Locations: Viking Clinical Site #1097, Portland, Oregon  
+1 locations          
        
                            Viking Clinical Site #1097, Portland, Oregon
                            Viking Clinical Site #1126, Portland, Oregon
                     
        
            
        
     
                             
    
        
            
                
                                    Circadian Time Restricted Eating
                                
            
            
         
        
     
    
        
            
                The goal of this study is to learn more about how the time in which participants consume their meals relative to their personalized circadian rhythm influences their overall cardiometabolic health and weight. The investigators are hoping to discover if a circadian-based time restricted eating intervention will improve cardiometabolic health and decrease weight. The protocol is a 46 day prospective cohort study that includes both field and in-laboratory data collection in overweight and obese ind...  
Read More             
        
            
                The goal of this study is to learn more about how the time in which participants consume their meals relative to their personalized circadian rhythm influences their overall cardiometabolic health and weight. The investigators are hoping to discover if a circadian-based time restricted eating intervention will improve cardiometabolic health and decrease weight. The protocol is a 46 day prospective cohort study that includes both field and in-laboratory data collection in overweight and obese individuals. 
Read Less
            
         
    
        
            
            
                Ages:
                Between 18 years and 40 years
             
            
                Trial Updated:
                04/02/2024
             
         
        
            Locations: Oregon Health and Science University, Portland, Oregon         
        
                            Oregon Health and Science University, Portland, Oregon
                     
        
            Conditions: Circadian Rhythm, 
Cardiometabolic Health, 
Weight Loss, 
Cardiovascular Health, 
Time Restricted Feeding